Sinocelltech Group LimitedSSE: 688520

(688520)"Sinocelltech Group Limited"Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for the Controlled Subsidiary's Product SCT810

· Issued by Sinocelltech Group Limited via Shanghai Stock Exchange

Filed with SSE · Stock code 688520 · · 2 pages · Chinese

Summary by 6ix AI

The announcement includes details about the product, its development, and associated risks. The company emphasizes the uncertainties involved in clinical trials and the potential impact on its operations and financial performance.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688520sinocelltech-group-limitedannouncement-on-voluntary-disclosure-of-receipt-of-the-clinical-trial-approval-notice-for-the-controlled-subsidiarys-product-sct810

Release

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for the Controlled Subsidiary's Product SCT810

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Sinocelltech Group Limited on 6ix

Story so far

Earlier from Sinocelltech

Later from Sinocelltech

All Sinocelltech news releases